SCHEMBL29523344

SCHEMBL29523344

CC(C)(C)OC(=O)N=C(NC(=O)OC(C)(C)C)N1CC[C@@H](c2nc(-c3ccc(Nc4cccc(C(C)(C)C)c4)nc3)no2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.42
LMNA P02545 2/20 0.42
MAPT P10636 2/20 0.42
HTT P42858 2/20 0.42
MEN1 O00255 1/20 0.42
RECQL P46063 1/20 0.42
KMT2A Q03164 1/20 0.42
TUBB4A P04350 2/20 0.39
TUBB P07437 2/20 0.39
TUBA3C P0DPH7 2/20 0.39
TUBA1B P68363 2/20 0.39
TUBA4A P68366 2/20 0.39
TUBB4B P68371 2/20 0.39
TUBB3 Q13509 2/20 0.39
TUBB2A Q13885 2/20 0.39
TUBB8 Q3ZCM7 2/20 0.39
TUBA3E Q6PEY2 2/20 0.39
TUBA1A Q71U36 2/20 0.39
TUBA1C Q9BQE3 2/20 0.39
TUBB6 Q9BUF5 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22280553 1.00 SMN1; SMN2 (0.42) SMN1; SMN2LMNAMAPTHTTMEN1
SCHEMBL22265599 0.95 SMN1; SMN2 (0.42) SMN1; SMN2LMNAMAPTHTTMEN1
SCHEMBL22265596 0.95 SMN1; SMN2 (0.42) SMN1; SMN2LMNAMAPTHTTMEN1
SCHEMBL22265592 0.95 SMN1; SMN2 (0.42) SMN1; SMN2LMNAMAPTHTTMEN1
SCHEMBL29523141 0.88 LMNA (0.47) SMN1; SMN2LMNAMAPTHTTMEN1
SCHEMBL22280559 0.88 LMNA (0.47) SMN1; SMN2LMNAMAPTHTTMEN1
SCHEMBL29523162 0.85 SMO (0.42) SMN1; SMN2LMNAMAPTHTTSMO
SCHEMBL29523791 0.85 SMO (0.38) SMN1; SMN2LMNAMAPTHTTMEN1
SCHEMBL22265631 0.84 LMNA (0.49) SMN1; SMN2LMNAMAPTHTTMEN1
SCHEMBL22265627 0.84 LMNA (0.49) SMN1; SMN2LMNAMAPTHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590083-B2 Inhibitors of spinster homolog 2 (SPNS2) for use in therapy UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2026-03-31 US disclosed
US-20220089581-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089581-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY SPNS2, SPCS2, SMN1; SMN2 SMN1; SMN2 3/4885LMNA 2555/4885MAPT 22/4885
US-12590083-B2 Inhibitors of spinster homolog 2 (SPNS2) for use in therapy SPNS2, SLC20A2, S1PR2 SMN1; SMN2 636/4885LMNA 1207/4885MAPT 704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.